Home » Stocks » MEIP

MEI Pharma, Inc. (MEIP)

Stock Price: $3.02 USD 0.12 (4.14%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 339.82M
Revenue (ttm) 31.59M
Net Income (ttm) -45.11M
Shares Out 112.52M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.02
Previous Close $2.90
Change ($) 0.12
Change (%) 4.14%
Day's Open 2.93
Day's Range 2.93 - 3.03
Day's Volume 485,027
52-Week Range 0.72 - 4.46

More Stats

Market Cap 339.82M
Enterprise Value 172.36M
Earnings Date (est) Feb 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 112.52M
Float 99.97M
EPS (basic) -0.51
EPS (diluted) -0.58
FCF / Share 0.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 11.09%
Payout Ratio n/a
Shares Short 7.73M
Short Ratio 13.14
Short % of Float 7.73%
Beta 1.78
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 9.02
PS Ratio 10.76
PB Ratio 3.87
Revenue 31.59M
Operating Income -27.50M
Net Income -45.11M
Free Cash Flow 37.69M
Net Cash 167.46M
Net Cash / Share 1.49
Gross Margin 83.07%
Operating Margin -87.06%
Profit Margin -142.80%
FCF Margin 119.30%
ROA -12.15%
ROE -69.62%
ROIC -3,443.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.50*
(214.57% upside)
Low
5.50
Current: $3.02
High
13.00
Target: 9.50
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue28.914.921.6223.25------
Revenue Growth488.26%203.02%-93.02%-------
Gross Profit26.240.65-1.7618.25------
Operating Income-24.54-46.25-28.592.38-21.00-32.77-27.23-11.22-8.39-6.45
Net Income-46.02-16.82-40.072.67-20.86-32.69-27.15-11.19-7.52-6.78
Shares Outstanding91.0871.1441.4336.8134.4028.2020.0610.162.251.27
Earnings Per Share-0.51-0.75-0.970.07-0.61-1.16-1.35-1.10-3.35-5.34
Operating Cash Flow34.26-29.42-21.043.49-17.86-28.07-19.45-10.04-7.08-6.50
Capital Expenditures-0.89-0.22--0.05--0.02-0.05-0.04--0.05
Free Cash Flow33.36-29.64-21.043.44-17.86-28.08-19.50-10.08-7.08-6.55
Cash & Equivalents18374.4910353.5745.9263.7848.7935.576.203.86
Net Cash / Debt18374.4910353.5745.9263.7848.7935.576.203.86
Assets21082.6610555.7047.1664.7549.8136.556.374.17
Liabilities13234.7354.204.875.514.964.621.681.772.37
Book Value78.2247.9350.4650.8441.6559.7945.1934.874.601.79
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MEI Pharma, Inc.
Country United States
Employees 51
CEO Daniel P. Gold

Stock Information

Ticker Symbol MEIP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MEIP
IPO Date December 19, 2003

Description

MEI Pharma, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.